We’re supporting clients through every stage of their brand and product lifecycle.
Our centers of expertise span therapeutic areas, markets and geographies, and are underpinned by these four core research principles:
Mobile navigation menu modal
comprehensive real-world patient data for Alzheimer’s disease using Therapy Watch, our syndicated market tracking solution
Therapy Watch is pleased to announce the readout of its first report covering Alzheimer’s disease...
We are delighted to announce that two abstracts from the Therapy Watch EU5 Rheumatology study have been accepted for inclusion in the EULAR Abstract..
This Acute Myeloid Leukemia infographic offers an introduction to the real-world patient data collected by our Therapy Watch study.
The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US.
The new pulmonary arterial hypertension (PAH) study is launching in the US market, with new markets being added in early 2024. .
Our Rheumatology market snapshot offers an introduction to the real-world patient data collected by our Therapy Watch study.
The new Therapy Watch postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry.
An introduction to the real-world patient data collected by our Therapy Watch migraine study.
Therapy Watch, with expansion of global COVID-19 tracker, now includes Australia, Canada, Japan, and Greece to have coverage of 16 markets.
New developments across the syndicated portfolio. Helen Parfitt will lead the new business unit and Sarah Brown joins as Head of Portfolio.
Latest report presents a view of the systemic lupus erythematosus (SLE) and lupus nephritis (LN) markets capturing the impact of new product launch.
Rapport is our monthly newsletter where we share our latest expertise and experience.
